Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Idarucizumab (Primary) ; Dabigatran etexilate
- Indications Blood coagulation disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 Planned End Date changed from 20 Aug 2017 to 1 Sep 2017.